Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 

13 protocols found



Protocol No. Title Status
AALL08B1 Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Open
AAML1331 A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid Open
APEC1621A NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 subprotocol of LOXO-101 in patients with tumors harboring actionable NTRK fusions Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621E NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations Open
APEC1621F NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621SC NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol Open
UW13090 TCR-a/b+ and CD19+ depleted KIR/KIR ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors Open
UW14108 Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (CCTL019A2205B) Open
UW17094 Nurse-Led Parent Educational Discharge Support Strategies (PEDSS) for Children Newly Diagnosed with Cancer Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open (affiliates only)